DMAC

Diamedica Therapeutics Stock Analysis

AI Rating

Fair
  • Quality0/10
  • Growth↓ 0/10
  • Momentum↑ 8/10
Diamedica Therapeutics sales and earnings growth
DMAC Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -26.79%
  • FCF Y/Y↓ -42.60%
Diamedica Therapeutics gross and profit margin trends
DMAC Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -90.10%
Diamedica Therapeutics net debt vs free cash flow
DMAC Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Diamedica Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗